戻る Agenda
Precision Medicines in Clinical Trials: Understanding and Overcoming Barriers to Adoption
Session Chair(s)
Anita Nelsen
Executive Vice President, Translational Medicine
Parexel, United States
Precision Medicines in Clinical Trials (PMCT) are demonstrably impactful in drug development yet are not widely adopted by industry. This forum explores reasons for low adoption from the viewpoints of scientists, drug developers and regulators and explores solutions.
Learning Objective : Describe the value of precision medicine trials (PMCT) as an innovative approach to drug development; Identify the regulatory, scientific, operational and technical challenges and barriers to the execution of these trials.; Explain key considerations for precision medicine trial design and execution.
Speaker(s)
Academic Perspective from Korea
Yeul Hong Kim, MD, PHD
Korea University Anam Hospital, Korea, Republic of
Professor, Section of Medical Oncology, Department of Internal Medicine
Panelist
Edward Abrahams, PHD
Personalized Medicine Coalition, United States
President
Panelist
Rebecca Blanchard, PHD
CRISPR Therapeutics, United States
Vice President, Translational Pharmacology